The objective of the present study was to develop empagliflozin and metformin hydrochloride extended release tablets, consisting of immediate release empagliflozin and extended release metformin hydrochloride in a single tablet. Impact of various formulation variables and critical process parameters on drug release of immediate release part was studied. Direct blending process was employed to formulate immediate release part empagliflozin and compressed along with extended release part metformin hydrochloride into bilayer tablets. Analysis of variance was used to assess impact of various formulation variables on immediate release part drug release. A 32 (two factor, three level) factorial design was employed to study the effect of independent variables (binder concentration [hydroxy propyl cellulose] and disintegrant [croscarmellose sodium] concentration) on dependent variable (drug release at 30 min). Optimization was done by fitting experimental data to the software program (design expert). The design space for formulation variables and its influence on drug release was developed. Fabricated tablets were characterized for various physicochemical parameters. The optimized formulation showed desired drug release of empagliflozin from immediate release part at 30 min as 84.0% ± 1.03. Empagliflozin and metformin hydrochloride extended release tablets were successfully developed by employing direct blending approach for immediate release part formulae optimization and formulation optimization of immediate release part was facilitated by experimental design.
Cite this article:
Rajarao Chinta, Rohini P. Formulation development of Empagliflozin and Metformin hydrochloride extended release Tablets: Optimization of Formulation using statistical experimental design. Research J. Pharm. and Tech 2021; 14(3):1201-1208. doi: 10.5958/0974-360X.2021.00214.6
1. Goldman JD. Combination of empagliflozin and metformin therapy: A consideration of its place in type 2 diabetes therapy. Clinical Medicine Insights Endocrinology and Diabetes. 2018; 11: 1-11.
2. International Conference on Harmonization, ICH Q8 (R2), Pharmaceutical Development: ICH Harmonized Tripartite Guideline, Geneva, 2009.
3. Dayal P et al. Box-Behnken experimental design in the development of a nasal drug delivery system of model drug hydroxyurea: Characterization of viscosity, In vitro drug release, droplet size and dynamic surface tension. AAPS Pharm. Sci. Tech. 2005; 6(4): 573-585.
4. Rekha Kallam et al. Formulation and Evaluation of Extended Release Matrix Formulation of Metoprolol Succinate. Research J. Pharm. and Tech. 2011; 4(1): 160-164.
5. Barde L.N. et al. Development and In Vitro Evaluation of Extended Release Matrix Tablet of Metoprolol Succinate. Research J. Pharm. and Tech. 2010; 3(3): 748-752.
6. Kothawade PI et al. Design and Evaluation of Sustained Release Matrix Tablet of Metformin Hydrochloride. Research J. Pharm. and Tech. 2010; 3(2): 522-525.
7. UD Shivhare et al. Preparation and Evaluation of Metformin Hydrochloride Microcapsules. Research J. Pharm. and Tech.2009; 2(3): 559-562.
8. UK Patil et al. Formulation and Evaluation of Controlled Release Microspheres Containing Metformin Hydrochloride. Research J. Pharm. and Tech. 2009; 2(1): 176-179.
9. M. Sujatha Kumari et al. Formulation Development of Metformin HCl and Repaglinide Bilayer Tablets: A Novel approach to improve Therapeutic Efficacy. Research J. Pharm. and Tech. 2018; 11(9): 4119-4125.
10. Hamid Khan et al. Formulation and In-Vitro Evaluation of FDC Bilayer Matrix Tablets Containing Telmisartan as Sustained Release and Hydrochlorothiazide as Immediate Release. Research J. Pharm. and Tech. 2017; 10(4): 1085-1090.
11. Sonali Joshi et al. Bilayer Tablet Technology: A Novel Approach. Research J. Pharm. and Tech. 2013; 6(12): 1443- 1451.
12. Bolton S. Statistical applications in the pharmaceutical sciences. In: Lachman L, Lieberman HA, Kanig JL, editors. The Theory and Practice of Industrial Pharmacy, Bombay. 1987; 3rd ed: pp. 243-289.
13. Indian Pharmacopoeia. Ministry of Health and Family Welfare Government of India, 2010, 786.
14. Syed Irfan Ali, Bharath Rathna Kumar. P. Stability Indicating Simultaneous Estimation of Metformin and Empagliflozin in Pharmaceutical Tablet Dosage form by RP-HPLC. Asian J. Research Chem. 2017; 10(6): 783-788.
15. Sushil D. Patil et al. Development and Validation of Stability Indicating RP-HPLC Method for Empagliflozin. Asian J. Pharm. Ana. 2016; 6(4): 201-206.
16. Available from: URL: http://www.accessdata.fda.gov/ scripts/cder/dissolution/dsp Search Results. cfm. [Last accessed on 2020 March 09].